CONCENTRIX CORPORATION
boothcheck covers CONCENTRIX CORPORATION (CNXC) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed July 25, 2026.
• Concentrix runs customer-experience operations on contract for other companies across six verticals, the largest being technology and consumer electronics at 27% of revenue, and the whole book of about 10.0 billion dollars in revenue converted to a 5.2% trailing operating margin. • The defining risk is written into its own risk factors: ⟦Some emerging technologies, including AI, GenAI, RPA, ML, VOC, IVR, and IoT, may cause an adverse shift in the way certain of our existing business operations
Is CNXC overvalued? See what's priced in →
283 institutional managers reported holding CNXC in 13F filings for the quarter ended 2026-03-31. 44 opened new positions that quarter. Held by Vanguard Group, AQR Capital, FMR (Fidelity), among others. On the short side, 10.1M shares were sold short as of the 2026-06-15 count, about 16% of shares outstanding (9.3 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CNXC's share count grew 19.5% over the past five years even with $557.87M spent on repurchases. It pays a dividend, and has paid one every year in our records (5 and counting), raised 4 years straight. Cash returned over the past three years: $231.44M in dividends and $397.01M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at CNXC over the trailing three years: 2023: 3 buys totaling $64k; 2024: 4 buys totaling $116k; 2025: 6 buys totaling $288k; 2026: 2 buys totaling $64k. 16 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CNXC's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-08 | -3.5% | -13.1% |
| 2023-10-07 | +10.9% | +17.5% |
| 2024-01-30 | -16.4% | -31.6% |
| 2024-04-06 | +4.1% | +4.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CNXC's latest 8-K filings: 2026-07-24 (items 5.02, 9.01); 2026-06-29 (items 2.02, 9.01); 2026-05-01 (items 5.02); 2026-03-27 (items 5.02, 5.07, 9.01); 2026-03-24 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.